Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Takeya Sugimoto"'
Autor:
Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takakura, Eri Takase, Masanori Tanaka, Takahiro Kaki, Yuhei Harutani, Katsuyuki Furuta, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Toshio Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Cancer Medicine, Vol 13, Iss 4, Pp n/a-n/a (2024)
Abstract Background Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires cla
Externí odkaz:
https://doaj.org/article/936934c8acbe4ec093a80de605ccb236
Autor:
Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi, Yusuke Murakami, Eri Takase, Yuichiro Azuma, Masaru Maebeya, Takeya Sugimoto, Atsushi Hayata, Takahiro Hayakawa, Shinya Tamaki, Masanori Nakanishi, Shunsuke Teraoka, Hiroaki Akamatsu
Publikováno v:
Cancer Medicine, Vol 11, Iss 20, Pp 3743-3750 (2022)
Abstract Background First‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) sometimes causes lung injury, thereby affecting survival. Although pre‐existing interstitial lung abnormal shadow (pre‐ILS) increases
Externí odkaz:
https://doaj.org/article/8ce8e7d2fc4341d99d6345df94b68b97
Autor:
Nobuyuki Yamamoto, Yuichi Ozawa, Takeya Sugimoto, Yuichiro Azuma, Yuhei Harutani, Takanori Yoshikawa, Kuninobu Kanai
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Introduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naïve, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged ≥75 y
Externí odkaz:
https://doaj.org/article/9c2038878ed14ed7b537c26e00ac1389
Autor:
Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, Keita Nakaguchi, Masanori Tanaka, Takahiro Kaki, Katsuyuki Furuta, Koichi Sato, Eriko Murakami, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Yasuhiro Koh, Masanori Nakanishi, Kuninobu Kanai, Toshio Shimokawa, Nobuyuki Yamamoto
Background: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation. Methods: Patients with advanced cancer who had dyspnea at rest (numeric rating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053072e04eee67e8700506ed3cf47b14
https://doi.org/10.21203/rs.3.rs-2639256/v1
https://doi.org/10.21203/rs.3.rs-2639256/v1
Autor:
Akito Hata, Nobuyuki Katakami, Hiroaki Akamatsu, Nobuyuki Yamamoto, Jun Oyanagi, Keisuke Tomii, Yuichi Ozawa, Toshio Shimokawa, Takeya Sugimoto, Yasuhiro Koh, Daichi Fujimoto, Eriko Murakami
Publikováno v:
Anticancer Research. 41:911-917
Background/aim To explore the safety of osimertinib plus ramucirumab in patients with EGFR-mutated lung adenocarcinoma. Patients and methods Six advanced lung adenocarcinoma patients with EGFR mutation were treated with osimertinib 80 mg/day plus ram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b32a367e3a5f0f77e021754aab72fd1
https://doi.org/10.21873/anticanres.14844
https://doi.org/10.21873/anticanres.14844
Autor:
Akihiro Tamiya, Masaki Kanazu, Akito Hata, Takeya Sugimoto, Junji Uchida, Yuki Sato, Motohiro Tamiya, Shunichiro Iwasawa, Masaki Kokubo, Yasushi Fukuda, Katsuya Hirano, Satoshi Hara, Takashi Yokoi, Nobuyuki Yamamoto, D. Fujimoto
Publikováno v:
Investigational New Drugs. 39:853-859
Introduction/Background Durvalumab demonstrated a good efficacy and safety in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in the PACIFIC trial. Although a history of radiation pneu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25dd90ce62f6d6e9d7f3cab07a226ba
https://doi.org/10.1007/s10637-020-01060-8
https://doi.org/10.1007/s10637-020-01060-8
Autor:
Takeya Sugimoto, Daichi Fujimoto, Yuki Sato, Motohiro Tamiya, Takashi Yokoi, Yoshihiko Taniguchi, Aoi Hino, Akito Hata, Junji Uchida, Yasushi Fukuda, Satoshi Hara, Masaki Kanazu, Hirotaka Matsumoto, Masaki Kokubo, Nobuyuki Yamamoto
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 171
Durvalumab was safe and effective in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in a phase 3 trial (PACIFIC trial). Although a history of radiation pneumonitis (RP) has been repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9ff5c4263406ac4b41b9a98813465ec
https://pubmed.ncbi.nlm.nih.gov/35863254
https://pubmed.ncbi.nlm.nih.gov/35863254
Autor:
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto
Publikováno v:
European journal of cancer (Oxford, England : 1990). 166
This study aimed to determine the incidence and clinical course of epidermal growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT).We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb488f941faf1e952084b5ab48fa632
https://pubmed.ncbi.nlm.nih.gov/35278824
https://pubmed.ncbi.nlm.nih.gov/35278824
Autor:
Nahomi Tokudome, Nobuyuki Yamamoto, Eri Takase, Atsushi Hayata, Eriko Murakami, Yuichi Ozawa, Masanori Tanaka, Ryota Shibaki, Shunsuke Teraoka, Takeya Sugimoto, Takahiro Kaki, Nao Yamagata, Jun Oyanagi, Yasuhiro Koh, Katsuyuki Furuta, Hiroaki Akamatsu, Keita Mori, Yuhei Harutani, Yuka Okuda
Publikováno v:
The Oncologist
Background Although predictive value of immune‐related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) have been suggested by several studies, their assessments were insufficient because patients were categorized only by the o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7352b560f7a3ac0bcb3cbba9bd7b6739
https://doi.org/10.1634/theoncologist.2019-0299
https://doi.org/10.1634/theoncologist.2019-0299
Autor:
Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, Takanori Yoshikawa, Ryota Shibaki, Takeya Sugimoto, Katsuyuki Furuta, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroki Ueda, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(9)
While PD-1/L1 inhibitors are characterized by durable tumor control, they also prolong survival without prolongation of progression-free survival (PFS) in part of patients. However, little is known about the factors and mechanisms involved in this. B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4408f16c1a3de647fb466744ec400833
https://pubmed.ncbi.nlm.nih.gov/35037070
https://pubmed.ncbi.nlm.nih.gov/35037070